NPPA Fixes Retail Prices Of 4 Formulations, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of retail prices of 4 formulations under the Drugs (Prices Control) Order, 2013 based on the decision of the 123rd Authority meeting dated 10.05.2024.
This list includes Protech Telelinks, Samarth Life Science's Ceftazidime and Avibactam powder for concentrate for solution for infusion, Ravenbhel Healthcare, La Renon Healthcare's Vitamin D3 Oral Solution, Pure and Cure Healthcare, La Renon Healthcare's Telmisartan and Chlorthalidone Tablet, Pure and Cure Healthcare, La Renon Healthcare's Telmisartan and Amlodipine Tablet.
This came in the exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit, and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1. | Ceftazidime and Avibactam powder for concentrate for solution for infusion | Each vial contains Ceftazidime Pentahydrate IP eq. to Ceftazidime2.0gm Avibactam Sodium eq. to Avibactam 0.5gm | 1 Vial | M/s Protech Telelinks / M/s Samarth Life Sciences Pvt. Ltd. | 2074.74 |
2. | Vitamin D3 Oral Solution | Each 5ml contains: Cholecalciferol IP 600000 IU (In Nano Droplet form) | 1ml | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 11.63 |
3. | Telmisartan and Chlorthalidone Tablet | Each film-coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 12.50mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 7.39 |
4. | Telmisartan and Amlodipine Tablet | Each uncoated bilayered tablet contains: Telmisartan IP 80mg Amlodipine Besilate IP eq. Amlodipine 5mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 13.21 |
The notification further added:
- The manufacturer of the above-mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer under the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.
- The above-mentioned retail price applies only to the individual manufacturer/ marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued before this notification, stand(s) superseded.
To view the official notice, click the link below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd